Latest News and Press Releases

Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 ...

– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover,...

– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an...

– Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – ...

BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that...

– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --...

BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of...

BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of...

- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio,...

- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas...